ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Clinical trials for ALK-POSITIVE NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new ALK-POSITIVE NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for ALK-POSITIVE NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to outsmart resistant lung cancer
Disease control Not yet recruitingThis phase 4 trial tests whether combining two oral drugs—ensartinib and anlotinib—can shrink tumors or slow disease in people with ALK-positive non-small cell lung cancer that has become resistant to lorlatinib. About 80 adults with advanced (stage IIIB-IV) cancer will receive t…
Matched conditions: ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE4 • Sponsor: Qiming Wang • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for ALK lung cancer: first human trial of AQUA07 begins
Disease control Not yet recruitingThis early-stage trial tests a new oral drug called AQUA07, alone or with another drug (lorlatinib), in about 102 people with ALK-positive non-small cell lung cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see how the bod…
Matched conditions: ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC